To further explore the potential of PKM as a biomarker for the changes in glucose metabolism that occur over the course of AD progression, we developed a Meso Scale Discovery (MSD)-based ELISA specifically designed to measure PKM levels in CSF. The gene discussed is PKM; the disease is Alzheimer disease.